Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 216 for “"PD1"”.
-
Analysis of soluble high-affinity PD1 variants
… a checkpoint inhibitor therapeutic to inhibit PD1/PD-L1 signalling. Mesenchymal stem cells (MSCs) offer an alternative drug delivery method for delivering this treatment to the pancreas due to their ability to infiltrate tumours and deliver a therapeutic pay load. In this study soluble PD1 …
-
Inhibitors of the PD1/PD-L1 interaction: missteps, mechanisms and mysteries
… PD-L1 binds to its receptor programmed death 1 (PD1) on T cells, inhibiting T cell responsiveness to antigenic stimuli. Blockade of the PD1/PD-L1 pathway removes this negative signal and restores anti-tumour immunity. While this blockade of PD1/PD-L1 is well established through the use of …
-
DELINEATING GUT-MEDIATED RESPONSE AMONG MELANOMA PATIENTS UNDERGOING ANTI-PD1 IMMUNOTHERAPY
… followed at baseline and over the course of anti-PD1 immunotherapy, collecting fecal and blood samples, from which we surveyed the gut microbiota, metagenome, and systemic immune profile. For validation, fecal samples from tumor-free subjects were used as reference; gut variability measures were …
-
Investigating biomarkers of response to anti-PD1 therapy in Hepatocellular Carcinoma
HCC accounts for over 830,000 deaths annually, with a poor 5-year survival rate of 5%. It is commonly detected at an advanced stage, where there are limited treatment options for patients and poor efficacy from the treatment options that are currently available. Owing to the high level of …
-
Changing landscape of immuno-oncology: CAR-T therapy and PD1/PDL1 blockade
… of the programmed cell death protein 1 (PD1) allowed researchers to create novel antibodies that inhibit immunosuppression. PD1 located on T cells, binds to PDL1 on cancer and stromal cells. This interaction induces exhaustion and anergy in infiltrating T cells, thereby prevent T cells …
-
Characterisation of PD1-expressing CMV-specific CD8+ T-cells in healthy donors and cancer patients.
… CD8+ T-cells is the immune checkpoint regulator PD1. Due to the remarkable success of antibody-mediated PD1 inhibition in the treatment of cancer this is one of the most important proteins in medical research at the current time. These therapeutic successes have arisen due to the presence of PD1 …
-
Identifikation pathogenetischer Signaturen für die Dermatomyositis – mit Fokus auf PD1 und Typ I Interferon Signalwegen
… dysregulierte Immuncheckpoint-Inhibition über PD1 und dessen Liganden. Die „Typ I Interferon Hypothese“ wird untermauert durch die bekannte, distinkte Interferon Typ 1 Signatur, die im Muskel, Blut und Hautgewebe von DM Patienten gefunden werden kann. In dieser Arbeit wurde auf verschiedenen …
-
Optimisation of a novel metabolic assay to study the features of PD1+ T cells in viral infection
T cells are a family of specialised adaptive immune cells which are central to the identification and elimination of viral infections. The dynamic activity of T cells is underpinned by highly regulated metabolic processes, and thus there is a growing interest in the field of immunometabolism as a …
-
Targeting The Erβ/Her Oncogenic Network In Lung Cancer: Synergistic Antitumor Interaction And Potentiation Of Anti-Pd1 Efficacy
… that target programmed death receptor 1(PD1) or its ligand (PD-L1) have proven great efficacy for certain patients with lung cancer. Patients who respond to these agents tend to have durable effects and longer survival outcomes; however, only 20-29% of patients are predicted to respond. …
-
Investigating the Target Landscape and Mechanisms of Resistance to PD1-IL2v through a Combined Preclinical and Translational Approach
… systemic toxicity. To address these limitations, PD1-IL2v, a novel immune-cytokine, was developed, designed to block PD-1 signaling while delivering IL-2R agonism in cis to PD-1+ CD8+ T cells. This thesis project provides an overview of the efficacy and limitations of PD1-IL2v, with the objective …
-
Μελέτη των CD8+ T λεμφοκυττάρων με φαινότυπο εν είδη βλαστικών (stem-like) κυττάρων σε καρκινώματα κεφαλής-τραχήλου
… της εξάντλησης τα κύτταρα αποκτούν τον φαινότυπο PD1+CD8+TCF1+ , όπου σε αυτή την κατάσταση τα κύτταρα φαίνεται να έχουν κάποιες ιδιότητες των αρχέγονων κυττάρων που μπορούν να πυροδοτήσουν την ανοσιακή αυτοανανέωση. Στο τελικό στάδιο της εξάντλησης τα κύτταρα χάνουν τις αρχέγονες ιδιότητες, …
-
Combining Vitamin D with Programmed Death 1 Blockade in Head and Neck Cancer
… cell carcinoma (HNSCC). These antibodies (α-PD1) have led to remarkable outcomes in this patient population. However, only a small fraction of HNSCC patients respond favorably to these agents highlighting the need for developing novel strategies that safely enhance the efficacy of α-PD1 …
-
Immune-Related Adverse Events (irAEs) of Immune Checkpoint Inhibitors (ICIs) in Advanced Melanoma Patients
… and anti-programmed cell death 1(anti-PD1) antibodies (nivolumab and pembrolizumab), have been shown to have a beneficial effect in treating melanoma but their risk of immune-related hypothyroidism (ir-hypothyroidism) in elderly patients from a real-world setting is limited. Objective …
-
Cytotoxicity, exhaustion, and immunosenescence in CD8+ T cells during aging and infection
… I examined how programmed cell death protein 1 (PD1) blockade affects CD8+ T cells in aged mice exposed to lethal microbial exposure (NME). I demonstrate that infection exacerbates CD8+ T cell exhaustion in aged mice, with increased expression of inhibitory receptors (PD1) and diminished effector …
-
Development of an MSC-based immune checkpoint inhibiting cell therapy
… since programmed cell death protein 1 (PD1) monoclonal therapies demonstrated notable efficacy with reduced toxicity. Despite its progress to date, several challenges persist, including a non-inflammatory tumour microenvironment (TME), constraints on drug delivery, and suboptimal binding …
-
Exercise to boost the immune system and optimise immunotherapy responsiveness
… with anti-Programmed Cell Death Protein 1 (PD1), compared with no exercise and isotype controls. TME immune populations were analysed by flow cytometry and immunofluorescence. Tumour and liver tissues were assessed for necrosis and metastases. Results: In healthy volunteers, exercise …
-
Peptide Radio Receptor Therapy might sensitize to immunotherapy by increasing expression of checkpoint molecules in patients with neuroendocrine tumors
… a subset of 14 patients. We detected elevated PD1 expression on CD4+ and CD8+ T cells of NET patients compared to healthy controls. PD1 expression was enhanced after PRRT but declined with increasing cycles. We also observed increasing expression of HLA-DR when PD1 was downregulated on T cells, …
-
Fetal alcohol syndrome: changes in transcriptional activation in the cerebellum caused by ethanol exposure during neurodevelopment
… by EMSAs. On the first post-natal day (PD1), there was decreased activation of these transcription factors in the in utero ethanol-exposed (E) group relative to the controls. There were no corresponding decreases in PD1 protein amounts of components of AP1 and NF-kB. Indices of oxidative …
Page 1 of 11